Abstract: The present invention relates to therapeutic uses of cyclosporin A to reduce adverse effects of neural injury.

Abstract: An aqueous pharmaceutical suspension consisting essentially of nevirapine hemihydrate having a particle size between about 1 and 150 microns in diameter.

Abstract: A capsule system for oral delivery of an active agent having low aqueous solubility generally includes, in combination with the active agent, a vehicle for preventing initial active agent dissolution within the gastrointestinal tract and an emulsifier for promoting self-emulsification of the active agent and vehicle in the gastrointestinal tract. A capsule shell is provided for encapsulating the active agent, vehicle and emulsifier with the shell being formulated to open upon ingestion into the gastrointestinal tract and release the active agent and vehicle.

Abstract: A composition having at least one herbal compound and at least one homeopathic drug is useful for treating symptoms associated with menopause. Methods of preparing the composition and methods of treating, alleviating or otherwise mitigating the menopausal symptoms are also described.

Abstract: Sustained release dosage forms of high dose insoluble drugs such as ibuprofen and methods for their manufacture are disclosed.

Abstract: A sustained-release preparation which can release a highly water-soluble medicinally active ingredient over a long time and a process for the production thereof are provided. The preparation has a sustained-releasing layer formed by heating and melting a layer composed of both an aqueous ethylcellulose latex containing a plasticizer and a wax to miscibilize them.

Abstract: A suspension of a sparingly water-soluble acidic drug, especially, a nonsteroidal anti-inflammatory analgesic agent, which is stable for a prolonged period of time and is highly dissolvable, and a process for simply and easily producing the suspension. This suspension has a pH value of 2 to 5 and comprises a sparingly water-soluble acidic drug whose average particle size ranges from 1 to 15 &mgr;m, a polyglycerol fatty acid ester, a water-soluble polyhydric alcohol and water, optionally, together with an inorganic powder having an average particle size of 1 to 15 &mgr;m.

Abstract: The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.

Abstract: A method using at least one guar gum as the sole shape-retention and/or shaping agent in cosmetic compositions intended for a temporary shaping of keratin fibers, and a method for the temporary shaping and/or deformation of keratin fibers, in particular in the shape of a hairsetting, using this compound.

Abstract: This invention offers capsules for oral preparation which is useful for colon diseases such as colon cancer, ulcerative colitis, constipation and diarrhea and for systemic diseases such as osteoporosis and which does not undergo any change at all in stomach and in small intestine but firstly start to disintegrate upon arriving at large intestine and, at the same time, quickly release the drug therefrom wherein the capsule base therefor is hydroxypropylmethylcellulose (HPMC) or polyethyleneglycol-compounded HPMC, gelatin or agar and, on the surface of said capsule base in which powder or liquid containing a pharmacologically active substance is encapsulated, a double-coated structure comprising an inner layer consisting of a cationic copolymer and an outer layer consisting of anionic copolymer is formed.

Abstract: A water-in-oil type emulsified composition containing one or more types chosen from among a group consisting of one or more types of a specific polyether modified silicone, oil, water or water and ethyl alcohol as well as a water soluble polymer with a molecular weight of 2,000-300,000 whose content is 0.1-20 wt % of the total emulsified composition, an inorganic salt or amino acid salt whose content is 0.1-08 wt % of the total emulsified composition. It is possible to provide an emulsified composition which gives gloss to the hair or skin, is moist but not sticky and exhibits excellent stability by using, as the emulsifier, polyether modified silicone rather than a surfactant or an organic modified clay mineral.

Abstract: The application of a soluble calcium compound and the further application of a suitable fluoride material accomplish calcium remineralization of fingernails. The calcium and fluoride preparations are kept separate until used. The calcium preparation is rubbed into the nail prior to the application of the fluoride; the fluoride then combines with the calcium applied in the first step within the nail allowing the nail to become harder and stronger.

Abstract: A nasally administrable composition which contains physiologically active compounds such as insulin, calcitonin, prostaglandin (PG) derivatives, monoclonal antibodies or interleukin derivatives (IL), and is enhanced in the in vivo absorbability of the physiologically active compound when administered nasally. The compositions are prepared by mixing fine particulate of the physiologically active compound with fine particulate of carrier having a mean particle size from 15 &mgr;m to 300 &mgr;m, and particle surface area from 0.1 to 0.4 m2/g, a which adhere to the mucous membrane of the nasal cavity, and HPC—H as absorption accelerator.

Abstract: Devices and methods for enhancing the healing of wounds, especially chronic wounds (e.g., diabetic wounds), involving the use of keratinocytes are described. Keratinocytes are grown on a transplantable solid support (e.g., collagen-coated beads), and the keratinocyte-coated solid support is placed in an enclosure. The enclosure, in turn, is placed in the wound for use as an interactive wound healing promoter.

Abstract: The invention concerns a method for preparing a modified release of active principle. The method comprises the steps of mixing a powder composed of active principle, adjuvant or combinations thereof while heating and fluidizing in order to obtain individual grains, liquefying a lipid matrix agent composed of partial esters of alcohol with at least one fatty acid, coating the powder by spraying from 1 to 15% by weight of the final composition liquid lipid matrix agent over the individual grains, the spraying air pressure, and optionally the spraying rate varying throughout the coating operation and lowering the temperature of the combined product to allow the lipid matrix agent to solidify around the grains.

Abstract: An aqueous nebulizer suspension contains water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer. The suspension may be prepared by ultrasonication or jet milling techniques.

Abstract: A dosage form is disclosed comprising a wall that defines an injection-molded compartment housing a capsule comprising a drug formulation.

Abstract: The invention relates to a solid deodorant composition, which is essentially anhydrous and comprises, as a solidifying agent, a mixture of waxes containing at least one synthetic polyethylene wax having a melting point of greater than 80° C., and at least one wax of natural origin having a melting point of greater than 80° C., as well as at least one deodorant active principle and a process for reducing the flow of sweat, and for masking, improving or reducing the unpleasant smell resulting from the decomposition of human sweat by bacteria using said composition.

Abstract: An aqueous pharmaceutical suspension consisting essentially of nevirapine hemihydrate having a particle size between about 1 and 150 microns in diameter.

Abstract: A pharmaceutical tablet, with a break line aligned along a long dimension of the tablet, such that a twisting action, in which parts of the tablets on opposite sides if the break line are subjected to a rotational twisting force in respectively opposite senses, causes the tablet to break into two or more parts. The tablet is of the type which may be broken into two or more parts in order to ease swallowing or to allow administration of a partial dose.